Impact of serum retinol-binding protein 4 levels on regulation of remnant-like particles triglyceride in type 2 diabetes mellitus by Yamaaki Naoto et al.
Impact of serum retinol-binding protein 4
levels on regulation of remnant-like particles
triglyceride in type 2 diabetes mellitus
著者 Yamaaki Naoto, Yagi Kunimasa, Kobayashi Junji,
Nohara Atsushi, Ito Naoko, Asano Akimichi,
Nakano Kaoru, Liu Jianhui, Okamoto Takuya,
Mori Yukiko, Ohbatake Azusa, Okazaki Satoko,
Takeda Yoshiyu, Yamagishi Masakazu
journal or
publication title







Journal of Diabetes Research
Volume 2013, Article ID 143515, 5 pages
http://dx.doi.org/10.1155/2013/143515
Clinical Study
Impact of Serum Retinol-Binding Protein 4 Levels on
Regulation of Remnant-Like Particles Triglyceride in Type 2
Diabetes Mellitus
Naoto Yamaaki,1 Kunimasa Yagi,1 Junji Kobayashi,2 Atsushi Nohara,1
Naoko Ito,1 Akimichi Asano,1 Kaoru Nakano,1 Jianhui Liu,1
Takuya Okamoto,1 Yukiko Mori,1 Azusa Ohbatake,1 Satoko Okazaki,1
Yoshiyu Takeda,1 and Masakazu Yamagishi1
1 Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi,
Kanazawa 920-8640, Japan
2Department of General Medicine, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku 920-0293, Japan
Correspondence should be addressed to Kunimasa Yagi; diabe@med.kanazawa-u.ac.jp
Received 25 December 2012; Accepted 12 February 2013
Academic Editor: Aristidis Veves
Copyright © 2013 Naoto Yamaaki et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Although retinol-binding protein 4 (RBP4) associates with insulin resistance and remnant-like particles triglyceride
(RLP-TG) elevated in the insulin resistant state, few data exist regarding the relationship between RBP4 and RLP-TG. Subjects and
Methods. The study included 92 Japanese type 2 diabetic mellitus (T2DM) male patients (age 60.5 ± 13.6 years, body mass index
(BMI) 24.7±4.1 kg/m2, waist circumference (WC) 88.4±10.7 cm, andHbA1c (NGSP) 7.2±1.9%). Patients onmedications affecting
insulin sensitivity, including fibrates, biguanides, and thiazolidinedione, were excluded. Visceral fat area (VFA) and subcutaneous
fat area (SFA) were measured by computed tomography. Results. RBP4 levels showed a significant positive correlation with RLP-
TG (𝑟 = 0.2544 and 𝑃 = 0.0056), TG (𝑟 = 0.1852 and 𝑃 = 0.041), RLP-TG/TG (𝑟 = 0.23765 and 𝑃 = 0.0241), and age (𝑟 =
−0.2082 and 𝑃 = 0.0219), although there was no significant correlation with VFA, SFA, adiponectin levels, or homeostasis model
of assessment insulin resistance (HOMA-R). Multiple regression analysis revealed that RBP4 was an independent determinant of
RLP-TG (𝑃 = 0.0193) but was not a determinant of TG. Conclusions. RBP4 correlates positively with serum RLP-TG independent
of fat accumulation in T2DM. RBP4 may regulate remnant metabolism independent of glycemic control in T2DM.
1. Introduction
Retinol-binding protein 4 (RBP4) was originally identified as
a signal molecule, which transfers the intercellular signals for
insulin resistance [1]. Previous clinical studies have reported
that RBP4 is associated with the extent of systemic insulin
resistance and obesity [2, 3]. RBP4 has been shown to signifi-
cantly correlate with clinical features relating to insulin resis-
tance andmetabolic syndrome, including hyperlipidemia and
hypertriglyceridemia [4]. Furthermore, recent studies have
shown that RBP4mainly correlates with dyslipidemic profiles
in type 2 diabetes, especially in terms of hypertriglyceridemia.
The retention of remnant lipoproteins is known to fre-
quently occur in the insulin resistant state and in metabolic
syndrome. Impaired remnant metabolism is one of the
“residual cardiovascular risk factor” for atherosclerosis [5].
Remnant clearance is retarded in insulin resistant type 2
diabetics resulting in cardiovascular damage [6]. Even though
the cardiovascular risk associated with metabolic syndrome
has been well established, few data exist concerning the
relationship between RBP4 and lipoprotein remnants such as
remnant-like particles triglyceride (RLP-TG). Therefore, we
are investigating the relationship between RBP4 and serum
lipoprotein levels, including RLP-TG, in Japanese diabetic
patients.
2. Patients and Methods
2.1. Patients. This study was approved by the ethical com-
mittee of Kanazawa University. Informed consents were
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obtained from all subjects. All patients were recruited from
Kanazawa University Hospital and its satellite hospital. Of
860 outpatients with type 2 diabetes mellitus, a total of 92
Japanese diabetic men (age 60.5 ± 13.6 years) with their
agreement of the computed tomographywere included in this
study.
Patients on medications affecting the individual insulin
sensitivity, including fibrates, biguanides, and thiazolidine-
dione, were excluded from this study [7, 8]. Patients with
other endocrine diseases or significant renal or hepatic
disease were also excluded. Obesity was defined as bodymass
index (BMI) ≥ 25 kg/m2, based on the criteria of the Japan
Society for the Study of Obesity [9]. Diabetes mellitus was
diagnosed according to World Health Organization criteria
[10] and/or receiving medications for diabetes mellitus.
2.2. Laboratory Measurements. BMI was calculated as weight
(kg) divided by height (m) squared. Waist circumference
(WC) at the umbilical level was measured in the exhalation
phase of respiration while standing.
Venous blood samples were performed after a 12-hour
overnight fast. Total cholesterol (TC) and triglyceride (TG)
were determined by enzymatic methods, and high-density
lipoprotein cholesterol (HDL-C) levels were measured by
a polyanion-polymer/detergent method. RLP isolation was
based on the removal of apo A-I-containing particles and
most apo B-containing particles, using an immunoseparation
technique, which has been shown to leave remnants of
both intestinal and hepatic origin in the unbound fraction.
Briefly, monoclonal antibodies to apo A-I and specific mon-
oclonal antibodies to apo B, which do not recognize par-
tially hydrolyzed, apo E-enriched lipoprotein remnants, were
immobilized on agarose gel. RLP-TG concentrations were
measured in the FHS plasma aliquots that had been frozen
at −80∘C until the time of analysis. Plasma was incubated
with the gel for 2 hours, after which the gel, containing
the bound (non-RLP) lipoproteins, was precipitated by low-
speed centrifugation. Triglyceride concentrations were then
measured in the unbound supinates. Blood glucose was mea-
sured with the glucose oxidase method and HbA1c by high-
pressure liquid chromatography. Plasma adiponectin levels
weremeasuredwith an enzyme-linked immunosorbent assay
kit (Otsuka Pharmaceutical Co., Tokushima, Japan), and
serum RBP4 was measured with Human RBP4 Competitive
ELISA kit (Adipogen, Seoul, Republic of Korea).
It is well known that RLP-TG has strongly correlated with
TG, which represents both overproduction and catabolism
of VLDL. This suggests that RLP-TG levels can reflect VLDL
overproduction. Therefore, we examined RLP-TG/TG ratio
as the focused index for remnant catabolism. Homeostasis
model of assessment insulin resistance (HOMA-R) is calcu-
lated using the following formula: fasting glucose (mg/dl) ×
fasting insulin (𝜇U/mL)/405.
2.3. Body Fat Distribution. All subjects underwent computed
tomography (CT) at the umbilical level to measure cross-
sectional visceral fat area (VFA) and abdominal subcuta-
neous fat area (SFA) using Fat Scan (N2 System Corp, Osaka,
Table 1: Clinical characteristics of the study subjects.
Age (years old) 60.5 ± 13.6
Body mass index (kg/m2) 24.7 ± 4.1
Fasting blood glucose 130.5 ± 33.5
HbA1c (NGSP) (%) 7.2 ± 1.9
Total cholesterol (mg/dL) 203 ± 43
Triglyceride (mg/dL) 165 ± 155
RLP-triglyceride (mg/dL) 34.4 ± 45.4
HDL-cholesterol (mg/dL) 51 ± 16
LDL-cholesterol (mg/dL) 118 ± 30
RBP4 (𝜇g/mL) 60.4 ± 35.0
Adiponectin (ng/mL) 6.84 ± 7.09
HOMA-R 2.88 ± 2.92
Waist circumference (cm) 88.4 ± 10.7
Visceral fat area (cm2) 110.6 ± 53.5
Subcutaneous fat area (cm2) 138.4 ± 75.2
Treatments for diabetic subjects
Sulphonylureas 16
Glinides 12
Alpha glucosidase inhibitors 17
Insulin injection 10
All data were indicated as mean ± SD.
Japan) [11]. VFA/SFA ratio was calculated as VFA divided by
SFA.
2.4. Statistical Analysis. All data are shown as mean ±
SD. Continuous variables were compared by ANOVA after
being adjusted for age, BMI, and sex. All statistical analyses
were conducted with JMP ver. 10.0.2 for Macintosh OSX
(SAS institute, NC, USA). A P value of less than 0.05 was
considered statistically significant.
3. Results
Baseline clinical characteristics of the patients are shown in
Table 1. Our previous report showed that poorly controlled
type 2 diabetic men had more unfavorable lipid profiles than
women, thus resulting in decreased lipolysis of plasma TG-
rich lipoproteins [12]. Therefore, only type 2 diabetic men
were enrolled in this study.
Relationships between RBP4 and other clinical parame-
ters were shown in Table 2. RBP4 showed significant positive
correlation with TG (𝑟 = 0.1852 and 𝑃 = 0.041) (Figure 1(a)),
RLP-TG (𝑟 = 0.2544 and 𝑃 = 0.0056) (Figure 1(b)), WC
(𝑟 = 0.1919 and 𝑃 = 0.0336), and negatively correlated
with age (𝑟 = −0.2082 and 𝑃 = 0.0219). RBP4 also showed
good correlation with RLP-TG/TG (𝑟 = 0.2376 and 𝑃 =
0.0241) (Figure 1(c)). Importantly, there was no significant
correlation between RBP4 and HOMA-R.
RLP-TG showed positive correlation with TC (𝑟 = 0.2894
and 𝑃 = 0.0017), TG (𝑟 = 0.6732 and 𝑃 < 0.0001), HbA1c
(𝑟 = 0.3506 and 𝑃 = 0.0011), HOMA-R (𝑟 = 0.3527 and 𝑃 =
0.0054), RBP4 and negative correlationwith age (𝑟 = −0.3377
and 𝑃 = 0.0003), and HDL-C (𝑟 = 0.3682 and 𝑃 < 0.0001).
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Table 2: Pearson correlation coefficients in the 92 patients with type
2 diabetes mellitus.
RBP4 TG RLP-TG
RBP4 — 0.1852∗ 0.2544#
Triglyceride (TG) 0.1852∗ — 0.6732$
Remnant-like particle TG (RLP-TG) 0.2544# 0.6732$ —
Age −0.2082∗ −0.2810# −0.3337†
BMI 0.1433 0.0290 0.0824
Total cholesterol (TC) 0.1729 0.4297$ 0.2894#
HDL-C 0.0179 −0.3663$ −0.3682$
LDL-C 0.1047 0.1531 0.0292
Fasting plasma glucose 0.1214 0.1468 0.1794
HbA1c 0.1268 0.3054# 0.3506#
Visceral fat area (VFA) 0.1386 0.1295 0.1537
Subcutaneous fat area (SFA) 0.1559 0.0225 0.0460
Waist circumference (WC) 0.1919∗ 0.0427 0.0976
Adiponectin 0.0842 0.0857 0.1114
HOMA-R 0.0923 0.1670 0.3527#
TG and RLP-TG were logarithm transformed. ∗𝑃 < 0.05; #𝑃 ≤ 0.01; †𝑃 ≤
0.001; $𝑃 ≤ 0.0001.
Table 3: (a) Multiple regression analysis with RLP-TG as a depen-
dent variable and (b) Multiple regression analysis with TG as a
dependent variable.
(a)
Factors Standard error 𝑡 𝑝 (prob > 𝑡)
Age 0.005372 −3.47 0.0008∗
RBP4 0.001999 2.39 0.0193∗
VFA 0.001597 1.87 0.0649
Adiponectin 0.010075 −1.59 0.1154
BMI 0.034605 −0.36 0.7208
SFA 0.001799 −0.23 0.8218
(b)
Factors Standard error 𝑡 𝑝 (prob > 𝑡)
Age 0.004836 −3.59 0.0006∗
VFA 0.001434 2.40 0.0189∗
BMI 0.031260 −1.64 0.1044
RBP4 0.001792 1.46 0.1485
Adiponectin 0.009033 −1.39 0.1687
SFA 0.001654 −0.19 0.8494
TG showed positive correlation with TC (𝑟 = 0.4297 and
𝑃 < 0.0001), RLP-TG, HbA1c (𝑟 = 0.3054 and 𝑃 = 0.0042),
negative relationshipswith age (𝑟 = −0.2810 and𝑃 = 0.0023),
and HDL-C (𝑟 = −0.3663 and 𝑃 < 0.0001). Unlike RLP-TG,
TG did not have a significant correlation with HOMA-R.
To investigate which factors independently determined
RLP-TG and TG, we performed multiple regression analysis.
Multiple regression analysis with RLP-TG (log) (Table 3(a))
as an objective variable revealed that RBP4 and age had
independent relationships with RLP-TG. Multiple regression
analysis with TG as an objective variable showed that VFA
and age had independent relationships with TG, but RBP4
had no independent relationships with TG (Table 3(b)).
4. Discussion
In the present study, we showed for the first time that serum
RBP4 levels correlated with RLP-TG. Univariate analyses
showed that RBP4 was significantly associated with RLP-TG
and TG. There was no correlation of RBP4 with most of
the insulin-resistance-associated factors (adiponectin, VFA,
BMI, and HOMA-R) except for a weak correlation with
WC, even though most of these factors were significantly
correlated with RLP-TG. Furthermore, multiple regression
analysis revealed that RBP4 had an independent association
with RLP-TG, although RBP4 did not have an independent
association with TG levels.These results suggested that RBP4
could regulate TG metabolism especially at the remnant
lipoprotein level.
RBP4 was identified as a signal transferring protein
for insulin resistance. Therefore, we focused mainly on
its relationship with insulin-resistant states in this study,
although some reports have shown that RBP4 could play
a more important role in lipid metabolism than in insulin
resistance [13]. RBP4 correlates with serum TG levels in type
2 diabetic patients independent from liver fat content [14, 15].
Furthermore, some reports have shown that RBP4 correlates
with hypertriglyceridemia independent of insulin resistance
[4, 13, 16]. In this study, serum RBP4 levels significantly
correlated with parameters relating to RLP-TG and TG.
Among the generally accepted markers for insulin resistance,
no significant relationships were observed between RBP4
and BMI, VFA, HOMA-R, or adiponectin. WC showed a
relatively weak relationship with RBP4. The correlation with
WC is indirect and is usually considered as a surrogate
marker reflecting the extent of insulin resistance. Actually, the
appropriate cutoff value ofWC to detect metabolic syndrome
is still under discussion [17]. However, it is still unclear why
RBP4 correlated only with WC instead of VFA which is
closely related to insulin resistance. Imbalance of fat distri-
bution in the study groupmay explain this dissociation. Even
under these conditions, RBP4 can regulate TG metabolism
especially at the remnant level, but visceral fat accumulation
and factors associated with insulin resistance may not be the
main pathway for RBP4 to regulate TG metabolism.
Two possible mechanisms explaining the increased level
of RLP-TG could be presented, one is the decreased metab-
olism of TG caused by decreased LPL activity induced by
insulin resistance [18] and another is the overproduction of
TG. Decreased LPL activity accounts for a great deal of the
elevation of serum TG in insulin-deficient diabetes patients
[19, 20]. As the RLP-TG to TG ratio has been reported to
correlate with LPL activity [21], the result of a significant
and positive relationship between RBP4 and the RLP-TG to
TG ratio in this study suggests that decreased LPL activity
would have contributed much to the elevation of RLP-TG. In
addition, RBP4 carries ligands of retinoid X receptor (RXR),
and RXRmodulates the expression of several genes including
apoC-III, which is an inhibitor of the lipoprotein lipase [22,
23]. Based on the present findings and previous reports, RBP4




































































Figure 1: Relationship between serum RBP4 levels and logarithm transformed triglyceride (TG) levels (a), logarithm transformed RLP-TG
levels (b), and RLP-TG/TG ratio (c).
is thought to increase RLP-TG through the activation of RXR,
inducing the overexpression of apoC-III and decreasing LPL
activity in type 2 diabetic patients.
This study has several limitations. First, we did not
measured LPL activity. As the RLP-TG to TG ratio has
been reported to correlate with LPL activity [21], we used a
surrogate marker of RLP-TG to TG ratios for LPL activity.
Although direct measurement would be ideal, our current
results seemed to justify using a surrogatemarker to represent
LPL activity. Second, some patients were treated with insulin
or sulphonylureas, which might affect RBP4 metabolism.
However, these medicines were discontinued the day prior to
the examination, so the effect on remnant metabolism would
be minimized.
In conclusion, RBP4 correlates positively with serum
RLP-TG independent of markers reflecting insulin resistance
including visceral fat accumulation in patients with type
2 diabetes mellitus. These results suggest that RBP4 may
have a negative effect on remnant metabolism independent
of visceral fat accumulation, glycemic control, or factors
associated with insulin resistance.
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